Technology
Health
Pharmaceutical

Aridis Pharmaceuticals

$9.61
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.03 (0.31%) Today
-$0.19 (-1.94%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell ARDS and other stocks, options, ETFs, and crypto commission-free!

About ARDS

Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-105, AR-101, AR-401, AR-201, and AR-501. Read More The company was founded by Eric J. Patzer and Vu L. Truong in 2003 and is headquartered in San Jose, CA.

Employees
28
Headquarters
San Jose, California
Founded
2003
Market Cap
79.53M
Price-Earnings Ratio
Dividend Yield
Average Volume
1.03K
High Today
$10.00
Low Today
$9.80
Open Price
$10.00
Volume
477.00
52 Week High
$13.85
52 Week Low
$6.92

Collections

Technology
Health
Pharmaceutical
2018 IPO
US
North America

ARDS Earnings

-$1.97
-$1.54
-$1.10
-$0.67
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 13, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.